AUTODOC
26.3.2020 18:38:07 CET | Business Wire | Press release
Autodoc, Europe’s largest online retailer of car spare parts, is donating EUR 50,000 to the Stiftung Universitätsmedizin Essen foundation to support the fight against COVID-19. The researchers are studying the biology of the virus together with Chinese colleagues in a laboratory in Wuhan, China. The aim is to develop therapeutic options and preventive measures. As an internationally active company, Autodoc would like to become involved at a global level in the fight against the current pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005597/en/
Autodoc GmbH, based in Berlin, is an international company with online shops in 26 European countries. The employees come from all over the world. The current crisis also affects Autodoc employees, customers and suppliers to a high degree. Autodoc would like to take its responsibility as a company and actively participate in the fight against COVID-19. To this end, Autodoc is supporting researchers at the Universitätsmedizin Essen medical center and the Union Hospital in Wuhan in their search for special treatments against the virus.
According to Alexej Erdle, managing partner of Autodoc GmbH, “The corona crisis is a global pandemic that affects us all. We are an international company. That is why we feel a clear responsibility here to contribute to solving this crisis. Every day we see what can be achieved when people from different countries work together, just as the researchers from Essen and Wuhan are doing. Supporting their work is now the best way for us to do something that helps people all over the world, i.e. to fight this pandemic. With this donation, we want to set an example so that every individual as well as every company can think about how to get involved within the scope of their respective possibilities so that we can succeed in overcoming this challenge together.
Researchers against a global pandemic
Since the end of December 2019, the novel coronavirus, SARS-CoV-2, has been spreading at high speed. It is the trigger of the COVID-19 disease. The Institute of Virology and the Clinic for Infectiology at the Universitätsmedizin Essen medical center and the Clinic for Infectious Diseases at the Union Hospital in Wuhan have been working closely together for many years. In 2017, a joint research laboratory was founded in Wuhan. Numerous data and samples have been collected and recorded there since the beginning of the COVID-19 pandemic. Due to the number of cases in China, this results in a much larger database than is currently the case in Germany, for example. The laboratory is already in operation and well equipped, but money is still urgently needed to cover the running costs for material and personnel. Autodoc is now supporting the researchers’ work with a sum of EUR 50,000.
Jorit Ness, Managing Director of the University Medical Foundation, is very grateful for the support: “In the current situation, rapid help – which is at the same time sustainable – is essential. Thanks to the research cooperation between Essen and Wuhan, which has been in place for years, professional and established structures are now in place and can be used immediately. It is now important to make additional funds available for the evaluation of the extraordinarily large amounts of data and samples of disease cases. With the donation from Autodoc GmbH we have come a big step closer to our goal”.
Social commitment
Since its foundation in 2008, Autodoc has seen itself as an active part of society and is committed both ideologically and financially to helping disadvantaged social groups. Autodoc therefore regularly supports local initiatives in various European countries.
If you would like to support the research work in Essen and Wuhan, please visit https://www.universitaetsmedizin.de/forschung/corona/ and make a donation online. Or donate directly to:
Stiftung Universitätsmedizin Essen
Hufelandstraße 55
45147 Essen, Germany
E-mail: info@universitaetsmedizin.de
Internet: https://www.universitaetsmedizin.de/
Donation account:
IBAN: DE 0937 0205 0005 0005 0005
BIC: BFSWDE33
Reference: corona research
Autodoc GmbH – a brief profile
Autodoc GmbH is Europe’s leading online dealer for automotive spare parts. As the fastest-growing company in this sector with a 63% growth in turnover in the 2018 financial year to around EUR 415 million (2017: EUR 254 million), Autodoc is aiming to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media activities, technical support in the respective national language and demand-oriented product range composition with currently almost 2.5 million products from 545 brand manufacturers for 128 car brands. The online retailer offers a wide range of products from brake systems, body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heaters, repair kits and engine oil. In June 2018, the company celebrated its tenth anniversary. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In May 2019, the company opened a representative office on Kurfürstendamm in addition to its headquarters.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
